|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||166.97 - 170.71|
|52 Week Range||137.70 - 179.84|
|PE Ratio (TTM)||63.72|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||1.88 (1.12%)|
|1y Target Est||181.35|
ResMed's (RMD) wholly owned unit Brightree remains integral to the company's group for two full years with a consistent stretch of success.
Stryker’s (SYK) orthopedics products mainly include implants used in hip and knee joint replacements and trauma and extremities surgeries. Total orthopedics revenues increased from $1.1 billion in Q1 2017 to $1.2 billion in Q1 2018. Revenues from knee products increased from $391 million in Q1 2017 to $419 million in Q1 2018. Revenues from hip products increased from $320 million in Q1 2017 to $331 million in Q1 2018. Trauma and extremities products generated $389 million in Q1 2018 as compared with $352 million in Q1 2017. ...
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
Stryker (SYK) generated revenues of $3.2 billion in the first quarter of 2018 compared with $3.0 billion in the first quarter of 2017. The research and development expenses that Stryker incurred rose by $12 million from $192 million in the first quarter of 2017 to $204 million in the first quarter of 2018. On account of the increase in SG&A expenses, the total operating expenses incurred by Stryker rose from $1.4 billion in the first quarter of 2017 to ~$1.6 billion in the first quarter of 2018.
In this series, we’ll analyze what analysts think about the company, how its product lines have performed, and how its first-quarter financials look. Of the 27 analysts covering Stryker in June, 18 analysts have given the stock a “buy” or higher rating, while nine analysts have given it a “hold” rating. The mean rating for the stock is 2.0 with a target price of $181.36, implying upside potential of 7.5% over the stock’s closing price of $168.75 on June 14.
In Q1 2018, Stryker (SYK) generated $297 million from operating activities as compared with $151 million in Q1 2017. This increase was primarily due to lower recall-related payments and increases in income taxes payable and working capital. Stryker used $849 million on investing activities in Q1 2018 as compared with $146 million in Q1 2017. This increase was due to Stryker’s $697 million acquisition of Entellus in Q1 2018.
Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.
There are a number of reasons that attract investors towards large-cap companies such as Stryker Corporation (NYSE:SYK), with a market cap of US$60.74B. Doing business globally, large caps tend toRead More...
The whole of fiscal 2018 demonstrates an upbeat momentum for PetMed's (PETS) new order sales, primarily backed by aggressive advertising.
Medical-technology company Stryker Corp. said Wednesday it is not in discussions with Boston Scientific Corp. regarding a potential takeover. On Monday, The Wall Street Journal reported Stryker had made a takeover approach to Boston Scientific, a move that would create a medical-device giant and would be the latest effort to consolidate a corner of the health-care industry that has produced a raft of large deals lately. Stryker said in a filing with the Securities and Exchange Commission on Wednesday it doesn’t typically comment on these matters, but it chose to respond following market speculation about a possible deal for Boston Scientific.
CEO Blake Moret tells TheStreet he is bullish on U.S. manufacturing. Private equity is having trouble putting money to work, one veteran deal-maker tells TheStreet's sister publication The Deal. Bitcoin prices continue to be under pressure, reports TheStreet's Kinsey Grant.
On June 13, Stryker (SYK) said in a regulatory filing that it’s not in discussions with Boston Scientific (BSX) related to its acquisition. The company released the statement following rumors of a potential acquisition offer made by Stryker to Boston Scientific on June 11, as we reported in Boston Scientific Surges on Rumors of Takeover Bid from Stryker.
Medtech player Stryker isn't in discussions to acquire Boston Scientific, Stryker said Wednesday — prodding shares to pop as Boston Scientific stock toppled more than 6%.
U.S. stocks were little changed on Wednesday, ahead of a widely expected interest rate hike by the Federal Reserve, with focus on its guidance on the economy and monetary policy. With the 25 basis point rate hike almost certain, market participants will parse the central bank's statement for clues on whether it will raise rates three or four times in 2018.
U.S. stocks were flat on Wednesday ahead of the Federal Reserve's policy announcement, while media shares got a boost from a court approval for AT&T's $85 billion takeover of Time Warner. AT&T dropped 3.8 percent and weighed the most on the S&P telecoms index, which fell 2.6 percent. Twenty-First Century Fox surged 7.8 percent as Comcast Corp is expected to outbid Disney for some of its assets.
Stryker's shares rose 7 percent to $174 in premarket trading after falling 9 percent in the last two days. Boston Scientific's shares fell 6.8 percent to $31.60. A potential deal between Stryker and Boston Scientific would create a combined company with a market value of more than $110 billion.
Medical device maker Stryker Corp is not in talks to buy rival Boston Scientific Corp , the company said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday, two days after a media report of a potential deal between the two surfaced. Stryker's shares rose 7 percent to $174 in premarket trading after falling 9 percent in the last two days. Boston Scientific's shares fell 6.8 percent to $31.60.
The medical device firm issues an 8-K filing on the heels of a media report earlier this week that said it recently made a takeover approach to Boston Scientific.
Shares of Boston Scientific Corp. tumbled 6.4%, and Stryker Corp.'s stock shot up 6.4%, after Stryker said it was not in talks to buy Boston Scientific, dispelling speculation after The Wall Street Journal reported on Monday that Boston Scientific had been approached by Stryker. In a filing with the Securities and Exchange Commission, Stryker said in a statement: "While it is Stryker Corporation's (Stryker) longstanding practice not to comment on these matters, today Stryker issued the following statement in response to the market speculation about a proposal to acquire Boston Scientific Corporation: 'Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition.'" The medical technology products company's stock had plunged 9.2% in two days since the WSJ report, while Boston Scientific shares had rallied 5.9% and the S&P 500 had inched up 0.3%.
Stryker Corp. said it isn’t in talks with medical-device giant Boston Scientific Corp. about a potential acquisition, responding to a report that it had sought a deal. The Wall Street Journal reported two days ago that Stryker had approached Boston Scientific about a potential merger, sending the target company’s shares soaring. “Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition,” the Kalamazoo, Michigan-based company said in a regulatory filing Wednesday.
•...and sympathize with Stryker (SYK), which was the index's worst-performing stock for a second day in a row. The Dow Jones Industrial Average declined 1.58 points to 25,320.73, while the S&P 500 rose 0.2% to 2786.85, and the Nasdaq Composite added 0.6% to 7703.79. For starters, we pretty much know that the Fed is going to raise interest rates at its meeting tomorrow.
Dow Jones component J&J could engage in a bidding war to sweep Boston Scientific out from under Stryker, an analyst said Tuesday.